HARBOR Trademark

Trademark Overview


On Thursday, January 4, 2024, a trademark application was filed for HARBOR with the United States Patent and Trademark Office. The USPTO has given the HARBOR trademark a serial number of 98342071. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, August 7, 2024. This trademark is owned by Avidity Biosciences, Inc.. The HARBOR trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology
harbor

General Information


Serial Number98342071
Word MarkHARBOR
Filing DateThursday, January 4, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateWednesday, August 7, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Description of MarkThe mark consists of HARBOR text with the "O" as a helm and 3 parallel wavy lines underneath it.
Goods and ServicesTherapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesProviding medical and scientific research information in the fields of pharmaceuticals and biotechnology

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, January 4, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, January 4, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAvidity Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events


Event DateEvent Description
Thursday, January 4, 2024NEW APPLICATION ENTERED
Sunday, April 28, 2024NOTICE OF DESIGN SEARCH CODE E-MAILED
Sunday, April 28, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 7, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 5, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, November 5, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, July 31, 2024ASSIGNED TO EXAMINER
Wednesday, August 7, 2024NON-FINAL ACTION E-MAILED
Wednesday, August 7, 2024NON-FINAL ACTION WRITTEN